IL-10 and TGF-β1 gene polymorphisms in Greek patients with recurrent aphthous stomatitis.


Journal

Medicina oral, patologia oral y cirugia bucal
ISSN: 1698-6946
Titre abrégé: Med Oral Patol Oral Cir Bucal
Pays: Spain
ID NLM: 101231694

Informations de publication

Date de publication:
01 Sep 2022
Historique:
received: 06 02 2022
accepted: 04 04 2022
pubmed: 7 6 2022
medline: 27 8 2022
entrez: 6 6 2022
Statut: epublish

Résumé

Recurrent aphthous stomatitis (RAS) is one of the most frequent inflammatory disorders of the oral mucosa. Cytokines, which play an important role in RAS pathogenesis, participate directly or indirectly in normal, immunological and inflammatory processes and are secreted from cells belonging to innate and adaptive immunity as a consequence of microbial and antigenic stimuli. Gene polymorphisms in specific cytokines may predispose to RAS development. The aim of this study was the investigation and association of IL-10 and TGF-β1 gene polymorphisms with RAS. Study's cohort consisted of 60 Greek patients diagnosed with RAS, including 40 patients with minor, 10 patients with major and 10 with herpetiform aphthous ulcers. Forty age- and sex-matched control subjects were included in this study. DNA was extracted from whole blood samples of all patients and sequence-specific primers (SSP)-based polymerase chain reaction (PCR) was used for genotyping. Gene polymorphisms for cytokines IL-10 at loci -592 and -819 and for TGF-β1 at codon 10 were detected. Significant differences between patients with minor RAS and healthy controls were recorded for IL-10 genotypes distribution at position -592 (p=0.042) and -819 (p=0.045) with predominance of C/A and C/T genotypes in RAS patients, respectively. Also, in patients with minor and herpetiform aphthous ulcerations, heterozygous TGF-β1 genotype C/T at codon 10 was associated with increased risk of RAS (p=0.044 and p=0.020, respectively). These data provide evidence that genetic predisposition for RAS and possibly its specific clinical variants is related with the presence of gene polymorphisms for specific cytokines, including IL-10 and TGF-β1, which, in turn, may vary according to geographic origin and genetic background.

Sections du résumé

BACKGROUND BACKGROUND
Recurrent aphthous stomatitis (RAS) is one of the most frequent inflammatory disorders of the oral mucosa. Cytokines, which play an important role in RAS pathogenesis, participate directly or indirectly in normal, immunological and inflammatory processes and are secreted from cells belonging to innate and adaptive immunity as a consequence of microbial and antigenic stimuli. Gene polymorphisms in specific cytokines may predispose to RAS development. The aim of this study was the investigation and association of IL-10 and TGF-β1 gene polymorphisms with RAS.
MATERIAL AND METHODS METHODS
Study's cohort consisted of 60 Greek patients diagnosed with RAS, including 40 patients with minor, 10 patients with major and 10 with herpetiform aphthous ulcers. Forty age- and sex-matched control subjects were included in this study. DNA was extracted from whole blood samples of all patients and sequence-specific primers (SSP)-based polymerase chain reaction (PCR) was used for genotyping. Gene polymorphisms for cytokines IL-10 at loci -592 and -819 and for TGF-β1 at codon 10 were detected.
RESULTS RESULTS
Significant differences between patients with minor RAS and healthy controls were recorded for IL-10 genotypes distribution at position -592 (p=0.042) and -819 (p=0.045) with predominance of C/A and C/T genotypes in RAS patients, respectively. Also, in patients with minor and herpetiform aphthous ulcerations, heterozygous TGF-β1 genotype C/T at codon 10 was associated with increased risk of RAS (p=0.044 and p=0.020, respectively).
CONCLUSIONS CONCLUSIONS
These data provide evidence that genetic predisposition for RAS and possibly its specific clinical variants is related with the presence of gene polymorphisms for specific cytokines, including IL-10 and TGF-β1, which, in turn, may vary according to geographic origin and genetic background.

Identifiants

pubmed: 35660731
pii: 25352
doi: 10.4317/medoral.25352
pmc: PMC9445602
doi:

Substances chimiques

Codon 0
IL10 protein, human 0
TGFB1 protein, human 0
Transforming Growth Factor beta1 0
Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e426-e433

Références

Cell Mol Immunol. 2020 Jul;17(7):722-727
pubmed: 32523115
Immunol Invest. 2014;43(4):405-9
pubmed: 24564196
Eur J Immunogenet. 1997 Feb;24(1):1-8
pubmed: 9043871
J Oral Sci. 2000 Mar;42(1):15-9
pubmed: 10808270
Acta Med Iran. 2017 Nov;55(11):672-675
pubmed: 29307155
Crit Rev Immunol. 2012;32(1):23-63
pubmed: 22428854
Bioorg Med Chem Lett. 2008 Mar 15;18(6):1835-9
pubmed: 18294846
Minerva Stomatol. 2018 Jun;67(3):125-128
pubmed: 29332375
Circulation. 2000 Jun 20;101(24):2783-7
pubmed: 10859282
Arch Dermatol. 1998 Jul;134(7):827-31
pubmed: 9681346
Bioinformatics. 2006 Aug 1;22(15):1928-9
pubmed: 16720584
J Exp Med. 2003 Dec 15;198(12):1875-86
pubmed: 14676299
Immunobiology. 2010;215(1):81-7
pubmed: 19249119
Arch Oral Biol. 2018 May 22;93:3-11
pubmed: 29800802
Int J Oral Maxillofac Surg. 2000 Oct;29(5):375-80
pubmed: 11071244
Arch Oral Biol. 2007 Mar;52(3):268-72
pubmed: 17052682
Hua Xi Kou Qiang Yi Xue Za Zhi. 2016 Feb;34(1):27-31
pubmed: 27266194
Annu Rev Immunol. 2004;22:929-79
pubmed: 15032600
Oral Dis. 2006 Jan;12(1):1-21
pubmed: 16390463
Community Dent Oral Epidemiol. 1994 Aug;22(4):243-53
pubmed: 7924239
Oral Dis. 2020 Nov;26(8):1696-1705
pubmed: 32558109
J Immunol. 2000 Nov 1;165(9):4773-7
pubmed: 11045997
J Oral Pathol Med. 1992 Jan;21(1):21-5
pubmed: 1593490
J Clin Aesthet Dermatol. 2017 Mar;10(3):26-36
pubmed: 28360966
J Oral Pathol Med. 2012 Jan;41(1):80-5
pubmed: 21554403
Cytokine Growth Factor Rev. 2010 Oct;21(5):315-24
pubmed: 21112807
Dent Clin North Am. 2014 Apr;58(2):281-97
pubmed: 24655523
Medicine (Baltimore). 2017 Dec;96(52):e9533
pubmed: 29384969
Genes Immun. 2019 Jan;20(1):90-101
pubmed: 29550839
Immunol Lett. 2005 Jun 15;99(1):57-62
pubmed: 15894112

Auteurs

V Kounoupis (V)

Department of Oral Medicine and Pathology and Hospital Dentistry School of Dentistry, National and Kapodistrian University of Athens 2 Thivon St., Goudi 11527, Athens, Greece mar1georgaki@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH